259 related articles for article (PubMed ID: 8227183)
1. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin.
Vogel T; Guo NH; Krutzsch HC; Blake DA; Hartman J; Mendelovitz S; Panet A; Roberts DD
J Cell Biochem; 1993 Sep; 53(1):74-84. PubMed ID: 8227183
[TBL] [Abstract][Full Text] [Related]
2. Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells.
Presta M; Rusnati M; Urbinati C; Sommer A; Ragnotti G
J Cell Physiol; 1991 Dec; 149(3):512-24. PubMed ID: 1660485
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells.
Guo N; Krutzsch HC; Inman JK; Roberts DD
Cancer Res; 1997 May; 57(9):1735-42. PubMed ID: 9135017
[TBL] [Abstract][Full Text] [Related]
4. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor.
Taraboletti G; Belotti D; Borsotti P; Vergani V; Rusnati M; Presta M; Giavazzi R
Cell Growth Differ; 1997 Apr; 8(4):471-9. PubMed ID: 9101093
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation.
Vogel T; Guo NH; Guy R; Drezlich N; Krutzsch HC; Blake DA; Panet A; Roberts DD
J Cell Biochem; 1994 Mar; 54(3):299-308. PubMed ID: 8200910
[TBL] [Abstract][Full Text] [Related]
6. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo.
Calzada MJ; Zhou L; Sipes JM; Zhang J; Krutzsch HC; Iruela-Arispe ML; Annis DS; Mosher DF; Roberts DD
Circ Res; 2004 Mar; 94(4):462-70. PubMed ID: 14699013
[TBL] [Abstract][Full Text] [Related]
7. Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1.
Yu H; Tyrrell D; Cashel J; Guo NH; Vogel T; Sipes JM; Lam L; Fillit HM; Hartman J; Mendelovitz S; Panel A; Roberts DD
Arch Biochem Biophys; 2000 Feb; 374(1):13-23. PubMed ID: 10640391
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain.
Hamma-Kourbali Y; Bernard-Pierrot I; Heroult M; Dalle S; Caruelle D; Milhiet PE; Fernig DG; Delbé J; Courty J
J Cell Physiol; 2008 Jan; 214(1):250-9. PubMed ID: 17607711
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence.
Sage EH; Bassuk JA; Yost JC; Folkman MJ; Lane TF
J Cell Biochem; 1995 Jan; 57(1):127-40. PubMed ID: 7721952
[TBL] [Abstract][Full Text] [Related]
10. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1.
Merle B; Malaval L; Lawler J; Delmas P; Clezardin P
J Cell Biochem; 1997 Oct; 67(1):75-83. PubMed ID: 9328841
[TBL] [Abstract][Full Text] [Related]
11. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
12. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
13. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
14. Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1.
Guo N; Zabrenetzky VS; Chandrasekaran L; Sipes JM; Lawler J; Krutzsch HC; Roberts DD
Cancer Res; 1998 Jul; 58(14):3154-62. PubMed ID: 9679984
[TBL] [Abstract][Full Text] [Related]
15. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis by thrombospondin-2.
Volpert OV; Tolsma SS; Pellerin S; Feige JJ; Chen H; Mosher DF; Bouck N
Biochem Biophys Res Commun; 1995 Dec; 217(1):326-32. PubMed ID: 8526929
[TBL] [Abstract][Full Text] [Related]
17. Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide.
Zabrenetzky VS; Kohn EC; Roberts DD
Cancer Res; 1990 Sep; 50(18):5937-42. PubMed ID: 2393863
[TBL] [Abstract][Full Text] [Related]
18. Endothelial proteoglycans inhibit bFGF binding and mitogenesis.
Forsten KE; Courant NA; Nugent MA
J Cell Physiol; 1997 Aug; 172(2):209-20. PubMed ID: 9258342
[TBL] [Abstract][Full Text] [Related]
19. Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis.
Guo NH; Krutzsch HC; Nègre E; Zabrenetzky VS; Roberts DD
J Biol Chem; 1992 Sep; 267(27):19349-55. PubMed ID: 1527055
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
